In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study.

1. Kidd SE, Hagen F, Tscharke RL et al. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci USA 2004; 101: 17258–63. 2. Pfaller MA, Messer SA, Boyken L et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990–2004). J Clin Microbiol 2005; 43: 2163–7. 3. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts— Second Edition: Approved Standard M27-A2. NCCLS, Wayne, PA, USA, 2002. 4. Bicanic T, Harrison T, Niepieklo A et al. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006; 43: 1069–73. 5. Aller AI, Claro R, Castro C et al. Susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994–1996 and 1997–2005. Chemotherapy 2007; 53: 300–5. 6. Espinel-Ingroff A, Fothergill A, Meter J et al. Testing conditions for determination of minimum fungicidal concentrations to new and established antifungal agents for Aspergillus spp. NCCLS collaborative study. J Clin Microbiol 2002; 40: 3204–8.